FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283462693> ?p ?o ?g. }

• W4283462693 endingPage "4725" @default.
• W4283462693 startingPage "4716" @default.
• W4283462693 abstract "In recent years, Coxsackievirus A2 (CV-A2) has become one of the main serotypes of enterovirus species A associated with hand, foot and mouth disease (HFMD) in China. It has also caused HFMD epidemics in many countries all over the world. Currently, there are no effective, preventive vaccines against it.A CV-A2 strain was isolated in RD cells and then adapted to grow in Vero cells. This is in compliance with guidelines for cell substrates allowed for human vaccines by the Chinese regulatory authority. Groups of newborn Kunming mice were inoculated on day 3 and day 9 using two formulations of candidate vaccines, empty particles and full particles. They were then challenged on day 14 at a lethal dose with a mouse-adapted strain.The mice in the control group all died within 14 days post-challenge whereas most of the mice in the candidate vaccine groups survived. It was found that the titers of neutralizing antibodies was dose-dependent in sera of immunized mice. The results also showed that the vaccine candidates stimulated a strong humoral immune response and protected the mice from disease and death. The virus loads in tissues or organs were significantly reduced and pathological changes were either weak or not observed in the immunized groups compared with those in Al(OH)3 control group. Preliminary mapping of the nucleotide and amino acid residues potentially related to cell tropism of the vaccine strain and virulence of the challenge strain was performed.The results showed that the RD cell-isolated and Vero cell-adapted CV-A2 strain is a promising vaccine candidate. This active immunization-challenge mouse model mimics the vaccination and then exposure to wildtype viruses, compared with passive immunization-challenge model, and is invaluable for efficacy evaluation in studies on multivalent vaccines containing CV-A2 against HFMD." @default.
• W4283462693 created "2022-06-26" @default.
• W4283462693 creator A5005032895 @default.
• W4283462693 creator A5011251776 @default.
• W4283462693 creator A5013514312 @default.
• W4283462693 creator A5033087095 @default.
• W4283462693 creator A5036065682 @default.
• W4283462693 creator A5052732719 @default.
• W4283462693 creator A5064433574 @default.
• W4283462693 creator A5065046382 @default.
• W4283462693 creator A5076873621 @default.
• W4283462693 creator A5081622648 @default.
• W4283462693 date "2022-08-01" @default.
• W4283462693 modified "2023-10-14" @default.
• W4283462693 title "Efficacy of Coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain" @default.
• W4283462693 cites W1482482570 @default.
• W4283462693 cites W1986010717 @default.
• W4283462693 cites W1996287598 @default.
• W4283462693 cites W1997367553 @default.
• W4283462693 cites W2001201654 @default.
• W4283462693 cites W2003914801 @default.
• W4283462693 cites W2015852059 @default.
• W4283462693 cites W2038866056 @default.
• W4283462693 cites W2053259407 @default.
• W4283462693 cites W2079268786 @default.
• W4283462693 cites W2099315132 @default.
• W4283462693 cites W2110767077 @default.
• W4283462693 cites W2127067203 @default.
• W4283462693 cites W2133625918 @default.
• W4283462693 cites W2137704955 @default.
• W4283462693 cites W2153545807 @default.
• W4283462693 cites W2158233251 @default.
• W4283462693 cites W2172465088 @default.
• W4283462693 cites W2341855390 @default.
• W4283462693 cites W2492114245 @default.
• W4283462693 cites W2517250564 @default.
• W4283462693 cites W2536325720 @default.
• W4283462693 cites W2560169275 @default.
• W4283462693 cites W2577379609 @default.
• W4283462693 cites W2588185991 @default.
• W4283462693 cites W2612250648 @default.
• W4283462693 cites W2621295861 @default.
• W4283462693 cites W2785784252 @default.
• W4283462693 cites W2791606848 @default.
• W4283462693 cites W2802562522 @default.
• W4283462693 cites W2885966692 @default.
• W4283462693 cites W2896218044 @default.
• W4283462693 cites W2902906917 @default.
• W4283462693 cites W2980000909 @default.
• W4283462693 cites W2990850031 @default.
• W4283462693 cites W2999211024 @default.
• W4283462693 cites W3009152961 @default.
• W4283462693 cites W3108259392 @default.
• W4283462693 cites W3118870653 @default.
• W4283462693 cites W3138810223 @default.
• W4283462693 cites W3168963293 @default.
• W4283462693 doi "https://doi.org/10.1016/j.vaccine.2022.06.021" @default.
• W4283462693 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35760737" @default.
• W4283462693 hasPublicationYear "2022" @default.
• W4283462693 type Work @default.
• W4283462693 citedByCount "3" @default.
• W4283462693 countsByYear W42834626932023 @default.
• W4283462693 crossrefType "journal-article" @default.
• W4283462693 hasAuthorship W4283462693A5005032895 @default.
• W4283462693 hasAuthorship W4283462693A5011251776 @default.
• W4283462693 hasAuthorship W4283462693A5013514312 @default.
• W4283462693 hasAuthorship W4283462693A5033087095 @default.
• W4283462693 hasAuthorship W4283462693A5036065682 @default.
• W4283462693 hasAuthorship W4283462693A5052732719 @default.
• W4283462693 hasAuthorship W4283462693A5064433574 @default.
• W4283462693 hasAuthorship W4283462693A5065046382 @default.
• W4283462693 hasAuthorship W4283462693A5076873621 @default.
• W4283462693 hasAuthorship W4283462693A5081622648 @default.
• W4283462693 hasBestOaLocation W42834626931 @default.
• W4283462693 hasConcept C10389963 @default.
• W4283462693 hasConcept C104317684 @default.
• W4283462693 hasConcept C105702510 @default.
• W4283462693 hasConcept C159047783 @default.
• W4283462693 hasConcept C159654299 @default.
• W4283462693 hasConcept C203014093 @default.
• W4283462693 hasConcept C2522874641 @default.
• W4283462693 hasConcept C2776548049 @default.
• W4283462693 hasConcept C2776872762 @default.
• W4283462693 hasConcept C2777888124 @default.
• W4283462693 hasConcept C2778022156 @default.
• W4283462693 hasConcept C2778889330 @default.
• W4283462693 hasConcept C2779070877 @default.
• W4283462693 hasConcept C2779120600 @default.
• W4283462693 hasConcept C2779261636 @default.
• W4283462693 hasConcept C2779341262 @default.
• W4283462693 hasConcept C32611913 @default.
• W4283462693 hasConcept C35693153 @default.
• W4283462693 hasConcept C55493867 @default.
• W4283462693 hasConcept C60987743 @default.
• W4283462693 hasConcept C86803240 @default.
• W4283462693 hasConcept C8891405 @default.
• W4283462693 hasConcept C89138240 @default.
• W4283462693 hasConceptScore W4283462693C10389963 @default.

• next